Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BRIGHTVIEW LLC

NPI: 1952727505 · LONDON, KY 40741 · Community/Behavioral Health Agency · NPI assigned 03/06/2014

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official NIEMAN, AMY controls 12+ related entities in our dataset. Read more

$579K
Total Medicaid Paid
16,389
Total Claims
9,804
Beneficiaries
20
Codes Billed
2020-07
First Month
2022-02
Last Month

Provider Details

Authorized OfficialNIEMAN, AMY (DIRECTOR)
Parent OrganizationBRIGHTVIEW LLC
NPI Enumeration Date03/06/2014

Related Entities

Other providers sharing the same authorized official: NIEMAN, AMY

ProviderCityStateTotal Paid
BRIGHTVIEW, LLC CINCINNATI OH $501.08M
COLUMN HEALTH, LLC LAWRENCE MA $32.69M
BRIGHTVIEW LLC LYNCHBURG VA $31.97M
BRIGHTVIEW LLC NICHOLASVILLE KY $11.47M
CHESAPEAKE TREATMENT SERVICES LLC EASTON MD $5.20M
CHESAPEAKE TREATMENT SERVICES OCEAN CITY LLC OCEAN CITY MD $4.74M
BRIGHTVIEW LLC LEXINGTON KY $2.06M
BRIGHTVIEW LLC CINCINNATI OH $1.13M
BRIGHTVIEW LLC PARIS KY $1.03M
BRIGHTVIEW LLC ASHEBORO NC $597K
BRIGHTVIEW LLC LOUISVILLE KY $29K
BRIGHTVIEW LLC GEORGETOWN KY $14K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 201 $5K
2021 15,758 $558K
2022 430 $15K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 5,991 3,258 $208K
T2023 Targeted case management; per month 684 521 $96K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 452 271 $51K
90837 Psychotherapy, 53 minutes with patient 855 594 $48K
90832 Psychotherapy, 30 minutes with patient 1,759 1,012 $43K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,511 849 $39K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 291 210 $25K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 787 486 $19K
90834 Psychotherapy, 45 minutes with patient 365 309 $13K
99406 1,930 1,159 $8K
H0001 Alcohol and/or drug assessment 263 197 $8K
90853 Group psychotherapy (other than of a multiple-family group) 570 322 $5K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 44 33 $4K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 78 75 $4K
H0038 Self-help/peer services, per 15 minutes 287 205 $3K
99205 Prolong outpt/office vis 31 24 $2K
81025 443 234 $2K
T1007 Alcohol and/or substance abuse services, treatment plan development and/or modification 15 14 $492.61
82075 15 15 $252.90
80305 18 16 $66.00